Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7920351 | 1.00 | PDCD1LG2 (0.41) | PDCD1LG2CD274CYP2C9EPHX2MAP4K4 | |
| Oxalic Acid SCHEMBL9459120 | 0.91 | CYP2C9 (0.46) | PDCD1LG2CD274CYP2C9EPHX2MAP4K4 | |
| SCHEMBL12090384 | 0.90 | MAP4K4 (0.46) | CYP2C9EPHX2MAP4K4CHRM2CHRM1 | |
| SCHEMBL6232040 | 0.89 | KDM4E (0.38) | PDCD1LG2CD274CYP2C9EPHX2MAP4K4 | |
| SCHEMBL12049777 | 0.85 | PDE9A (0.37) | PDCD1LG2CD274CYP2C9EPHX2MAP4K4 | |
| SCHEMBL28072254 | 0.82 | CYP2C9 (0.42) | PDCD1LG2CD274CYP2C9EPHX2MAP4K4 | |
| SCHEMBL19116698 | 0.80 | CD274 (0.47) | PDCD1LG2CD274CYP2C9EPHX2MAP4K4 | |
| SCHEMBL13123169 | 0.79 | CYP2C9 (0.40) | PDCD1LG2CD274CYP2C9EPHX2MAP4K4 | |
| SCHEMBL19077886 | 0.79 | CYP2C9 (0.41) | PDCD1LG2CD274CYP2C9EPHX2MAP4K4 | |
| SCHEMBL2076284 | 0.76 | HSD11B1 (0.46) | PDCD1LG2CD274CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| EP-3400221-B1 | PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
| CN-1208349-A | Composition for treating pain | LILLY CO ELI (US) | 1999-02-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | PDCD1LG2 848/4885CD274 1424/4885CYP2C9 2007/4885 |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | PDCD1LG2 848/4885CD274 1424/4885CYP2C9 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.